FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
Executive Summary
PhRMA Senior Counsel Jeffrey Francer offers three-step reform approach to loosening FDA’s restrictions, beginning with the 'low-hanging fruit' of talking with payers.
You may also be interested in...
FDA Soliciting Broad Range Of Comments From Industry On Regulatory Reform
FDA is addressing regulatory reform as part of President Trump's "two-for-one" executive order, and seeks industry comments to supplement the effort.
Payer Communications Safe Harbor Should Extend To Off-Label Uses – Industry
US FDA should apply same regulatory protections to manufacturer communications with payers about unapproved uses that agency draft guidance provides to information exchanges about investigational products, biopharma companies say.
'Safe Harbor' For Preapproval Information Exchange To Get Legislative Push
US Academy of Managed Care Pharmacy is developing language to protect exchange of clinical and economic information on pipeline products between manufacturers and healthcare decision-makers; safe harbor could find a home in legislation reauthorizing FDA user fee programs.